Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Conditions

• Multiple Myeloma
• Relapse Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Belantamab mafodotin — DRUG
  Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
• Carfilzomib — DRUG
  Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15 Cycles 2-8: 56 mg/m2 on Days 1/8/15 Cycles 9+: 56 mg/m2 on Days 1/15
• Pomalidomide — DRUG
  3 mg Day 1-21 of 28-day Cycle
• Dexamethasone — DRUG
  Cycles 1-4: 40 mg Days 1/8/15/22 Cycles 5+: 20 mg Days 1/8/15/22

Study Details

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.

Key Dates

Start date

May 30, 2023

Status verified

Dec 2025

Primary completion

Jul 1, 2028

Completion

Jul 1, 2028

Study Design

Enrollment

83 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Cohort 1: No Prior CAR T-Cell Therapy
  This cohort will consist of 19 participants who have not had CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone.
• Experimental: Cohort 2: Prior CAR T-Cell Therapy
  This cohort will consist of 64 participants who have had prior CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone.

Primary Outcome Measure

Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort) [ Time Frame: 6-24 months ]

Central Contacts

• Clinical Trials Intake
  1-855-702-8222
  [email protected]

Locations (1)

Find similar trials in Chicago, IL

Related Studies

• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
  PHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
• Personalized Autologous Transplant for Multiple Myeloma
  PHASE1 · Recruiting · Emory University · Atlanta, Georgia
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
  PHASE1 · Recruiting · Newave Pharmaceutical Inc · Chicago, Illinois